Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity...
The risk–benefit calculation for corticosteroid administration in the management of COVID-19 is complex and urgently requires data to inform the decision. The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with poor prognosis in both COVID-19 and cancer....
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer (BC). Due to the absence of targets such as HER2 or hormone receptors, early TNBC is treated with surgery and chemotherapy. Since TNBC is also considered the most immunogenic type of BC with tumor infiltrating...
Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. The researchers confirmed the association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs...
Immune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab have improved outcomes in metastatic renal cell carcinoma (mRCC) patients, but they are also associated with immune-related adverse events (irAEs). As observed in melanoma, the authors hypothesized that patients experiencing an...
Presentation slides and video from the 2020-2021 Advances in Cancer Immunotherapy™ Series - Tucson, AZ held virtually on October 31, 2020 are available here. Program Organizers Emmanuel Katsanis, MD – University of Arizona Ali McBride, PharmD, MS, BCPS, BCOP, FAzPA – University...
18 attachments
Immunotherapies have revolutionized the treatment of various cancers, but little is known about their symptomatic toxicity. Assessing these symptoms is best accomplished by asking the patients themselves. However, such reports are subjective and may face challenges as bonafide scientific data....
In the evolving immune-oncology landscape, numerous patients with cancer are constantly treated with immune checkpoint inhibitors (ICPIs) but among them, only sporadic cases with pre-existing hepatitis B virus (HBV) and hepatitis C virus (HCV) are recorded. Despite the global dissemination of...
Immune checkpoint inhibitors (ICI) block negative regulatory molecules, such as CTLA-4, PD-1 and PD-L1, in order to mount an antitumor response. T cells are important for antiviral defense, but it is not known whether patients with cancer treated with ICI are more or less vulnerable to viral...
Presentation slides and video from the 2020-2021 Advances in Cancer Immunotherapy™ Series - Seattle, WA held virtually on October 31, 2020 are available here. Program Organizers Shailender Bhatia, MD – University of Washington Petros Grivas, MD, PhD – University of Washington ...
16 attachments
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us